Diabetes and the Kidney

[1]  J. Dear,et al.  Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. , 2012, Kidney international.

[2]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy in obese patients with diabetes. , 2012, The New England journal of medicine.

[3]  Mark E Molitch,et al.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. , 2011, The New England journal of medicine.

[4]  H. Rayner,et al.  Systematic kidney disease management in a population with diabetes mellitus: turning the tide of kidney failure , 2011, Quality and Safety in Health Care.

[5]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[6]  K. Lipska,et al.  Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.

[7]  L. McMahon,et al.  The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  B. Zinman,et al.  Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). , 2009, Archives of internal medicine.

[9]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[10]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[11]  M. Zeier,et al.  Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. , 2008, Journal of the American Society of Nephrology : JASN.

[12]  O. Pedersen,et al.  Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes , 2008, Diabetes Care.

[13]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[14]  G. Remuzzi,et al.  Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[15]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[16]  Mark E. Williams,et al.  Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. , 2006, Kidney international.

[17]  N. Powe,et al.  International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. , 2006, Journal of the American Society of Nephrology : JASN.

[18]  Di Xie,et al.  Efficacy and safety of benazepril for advanced chronic renal insufficiency. , 2006, The New England journal of medicine.

[19]  E. Lewis,et al.  Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  J. Craig,et al.  Antihypertensive agents for primary prevention of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[23]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[24]  Andrzej S Krolewski,et al.  Regression of microalbuminuria in type 1 diabetes. , 2003, The New England journal of medicine.

[25]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[26]  N. Chaturvedi.  Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[27]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[28]  R. Wolfe,et al.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. , 1999, The New England journal of medicine.

[29]  M. Cooper,et al.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.

[30]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[31]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[32]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[33]  G. Blohmé,et al.  The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  P. Whelton,et al.  Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. , 1997, JAMA.

[35]  P. Whelton,et al.  Risk of End-stage Renal Disease in Diabetes Mellitus: A Prospective Cohort Study of Men Screened for MRFIT , 1997 .

[36]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[37]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[38]  G. Bakris,et al.  Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. , 1992, Kidney international.

[39]  C. Mogensen,et al.  The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy , 1983, Diabetes.

[40]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.